Partial Heart Transplant Growth and Hemodynamic Function in Piglets Authors: Lillian Kang, Berk Aykut, Herra Javed, Deani H McVadon, Randall S Prather, Douglas M Overbey, Joseph W Turek, Taufiek K Rajab Published: 2025 The most frequently replaced heart valve in infants is the pulmonary valve. Infant pulmonary valves are smaller than any available heart valve prostheses. Therefore, these valves are typically replaced with homografts. Homografts are procured from human cadavers using a process that does not retain viable cells. Without viable cells, homografts are unable to grow. This commits infants with homografts to serial valve replacements until an adult-size valve can fit. Partial heart transplantation is a new approach to solve this problem.1 The rationale for partial heart transplantation is that the heart valves contained in heart transplants grow.2 Partial heart transplants contain the necessary heart valve only, while the native ventricles are spared. Sparing the native ventricles eliminates graft ventricular dysfunction from acute and chronic rejection. Here, we compare pulmonary valve replacement with homografts and partial heart transplants in infant piglets. A total of 15 weight-matched piglets (Sus domesticus) were used (Institutional Animal Care and Use Committee protocol 2021-01163). For partial heart transplantation, donors (n = 3) and recipients (n = 3) were ABO matched. Two donors ubiquitously expressed green fluorescent protein (GFP) under control of the pCAGG promotor.3 The other piglets were wild-type. Donor piglets donated the pulmonary valve root and blood to prime the cardiopulmonary bypass circuit. Recipient piglets underwent induction immunotherapy with oral tacrolimus 0.05 mg/kg and mycophenolate 20 mg/kg, sternotomy, cardiopulmonary bypass, excision of the native pulmonary valve, and partial heart transplantation. Methylprednisolone 10 mg/kg was given before the graft was reperfused. Postoperatively, partial heart transplant recipients were immunosuppressed with tacrolimus titrated to a serum trough of 5 to 10 ng/mL, mycophenolate 10 mg/kg twice daily, and prednisolone tapered to 0.5 mg/kg twice daily. For homograft valve replacement, donors (n = 3) and recipients (n = 3) were not ABO matched. Donor piglets donated the pulmonary valve root, which was then cryopreserved for at least 1 month. Recipient piglets underwent sternotomy, cardiopulmonary bypass, excision of the native pulmonary valve, and homograft implantation. The cardiopulmonary bypass circuits were primed with blood from ABO matched blood donor piglets (n = 3). Homograft recipients did not receive immunosuppression. Postoperatively, all recipients underwent serial echocardiography. The primary outcome was the pulmonary valve gradient. The secondary outcomes were pulmonary valve regurgitation, pulmonary valve annulus diameter, and aortic valve annulus diameter. The experimental endpoint was reached when recipients had doubled in weight. Linear regression lines were compared to test the null hypothesis that the slopes are identical (Prism 10, GraphPad Software). The presence of GFP-positive donor cells was visualized using an excitation flashlight with 440- to 460-nm wavelength and a 500-nm long-pass filter (Xite Fluorescence System, Nightsea). The valves were also examined macroscopically and microscopically. Pulmonary valve replacement was performed at an average age of 48 days (range 35-54 days) and an average weight of 10.9 kg (range 9.1-13.4 kg). One recipient in the homograft group died prematurely from cardiac arrest during induction of anesthesia for echocardiography. All other recipients reached the experimental endpoint. As the recipients grew, the valve gradients in partial heart transplants remained low. In contrast, the valve gradients in homografts increased rapidly. This difference was highly significant (P < 0.01) (Figure 1A). No partial heart transplant had more than physiologic regurgitation. Two homografts had no more than physiologic regurgitation and 1 homograft had no more than mild regurgitation. The pulmonary valve annulus diameter increased in both partial heart transplants and homografts. However, the increase was significantly faster in partial heart transplants than in homografts (P < 0.01) (Figure 1A). In contrast, there was no difference in native aortic valve annulus growth (P = 0.11) (Figure 1A). On autopsy, the grown partial heart transplants remained GFP positive and had normal macroscopic and microscopic morphology (Figure 1B). Partial Heart Transplant Growth and Hemodynamic Function in Piglets (A) Echocardiography results. As recipients grew in weight, partial heart transplants (blue circles) had stable pulmonary valve (PV) gradients and adaptive growth of the PV annulus diameter. In contrast, homografts (red squares) had rapidly increasing PV gradients and a significantly lesser increase in PV annulus diameter. Growth of the native aortic valve (AV) annulus diameter was the same in both groups. (B) Partial heart transplant morphology. Following transplantation (top left), the grown partial heart transplants remained GFP positive (top middle and top right) and had normal macroscopic (middle) and microscopic (bottom) morphology. This study contributes preclinical evidence to support the use of partial heart transplants over homografts for valve replacement in infants. As recipients more than doubled in weight, partial heart transplants demonstrated stable valve gradients and adaptive valve growth. The grown partial heart transplants remained GFP positive, which confirmed the presence of donor cells, and had normal morphology. In contrast, homograft valve gradients rapidly increased above the threshold at which clinical guidelines recommend valve replacement. Homograft annulus diameters also increased but to a significantly lesser extent than partial heart transplant annulus diameters. This may be due to valve dilation rather than valve growth.4 There was no difference in growth of the native aortic valves, which served as control valves. These findings are clinically relevant because partial heart transplants can eliminate the need for serial valve replacements during childhood. Footnotes This work was supported by National Institutes of Health grants (R41HL169059,U42OD011140), the American Association for Thoracic Surgery, and the Brett Boyer Foundation. The authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References